Gate Bioscience expands its Lilly deal for hard-to-drug proteins, with potential value above $870m. Read the latest on the ...

RougeTx raised $58 million in Series A funding to advance its HHT treatment toward clinical development. See who backed the ...

M in an IPO to advance its Treg pipeline toward Phase II, with Lilly as collaborator and investor. Read the offering details.

Alector will receive $100M upfront as Genentech gains worldwide rights to its brain-penetrant GCase therapy for Parkinson’s.

Vaxcyte says its 31-valent VAX-31 vaccine met all primary endpoints in the OPUS-1 Phase III trial in adults aged 50 and older. Read the topline results.

Italfarmaco and VeriSIM Life will combine AI and HDAC expertise in a preclinical drug discovery deal worth over USD 100 ...

Italfarmaco has licensed JCR’s brain-penetrating Hunter syndrome therapy for the US, Europe and Latin America. Read the details of the international deal.

The FDA approved Jaypirca for first-line CLL/SLL, following trial results showing an 80% reduction in progression risk. See ...

U.S. cancer death rates fell through 2023, led by lung cancer gains, according to a new national report. Read the key ...

Researchers found that FAH’s nuclear function can drive CDK4/6 inhibitor resistance in HR+ breast cancer. Read what the ...

Celaid Therapeutics raised JPY 400m from Shionogi and Teikoku Ventures to prepare CLD-001 for US clinical trials. Read the ...

Sernova and Seraxis closed $11.2 million to fund merger and advance BetaNova’s type 1 diabetes cell therapy into Phase 1/2 ...